Brief: Cognition Therapeutics Completes FDA End-of-Phase 2 Meeting For Zervimesine In Alzheimer’s
10/07/2025 12:39
July 10 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS COMPLETES END-OF-PHASE 2 MEETING WITH FDA FOR ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE COGNITION THERAPEUTICS INC - DISCUSSED PHASE 2 RESULTS AND PHASE 3 PLAN WITH FDA Source text: ID:nGNXY0GXR Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB